December 22, 2020

Humanitarian activities of MultiplexDX

A shipment of 50,000 COVID-19 diagnostic kits developed by Slovak scientists arrived in Nairobi, Kenya on Monday, July 27th.

Source: Ministry of Foreign Affairs of  the Slovak Republic


SlovakAid, a humanitarian relief program of the Slovak Ministry of Foreign and European Affairs, sent a plane carrying COVID-19 supplies from Bratislava on Sunday, which arrived in Nairobi on Monday morning. The supplies include 50,000 vDETECT COVID-19 RT-qPCR diagnostic tests, one PCR thermocycler device to perform the tests, and 20,000 FFP2 respirators.

With the assistance of Ingrid Brocková, State Secretary of the Ministry of Foreign Affairs of the Slovak Republic, and Ján Lazar, State Secretary of the Ministry of the Interior of the
Slovak Republic, the relief supplies were presented to a representative of the Embassy of the Republic of Kenya in Austria on Friday, July 24th .

State Secretary Ingrid Brocková stated, “Kenya is one of the three development cooperation program countries of the Slovak Republic and our strategic partner in sub-Saharan Africa. It
is therefore understandable that we also want to help its people in the fight against the new coronavirus. I am glad that the humanitarian shipment also includes unique diagnostic tests, developed by a team of Slovak scientists.”

Pavol Čekan, founder of MultiplexDX, commented,

“We rapidly developed a new PCR test for COVID-19 that can reliably help diagnose early-stage patients. Having provided enough test kits to address the needs of Slovak laboratories, we turned our efforts to stepping up production for other countries, such as Kenya, that could benefit from our products.”

A shipment of 7,200 COVID-19 diagnostic kits produced by Slovak company MultiplexDX arrived in Lysychansk on December 4 th.

Source: Ministry of Foreign Affairs of  the Slovak Republic

On December 3 rd and 4 th , 2020, the Ambassador Extraordinary and Plenipotentiary of the Slovak Republic to Ukraine, Marek Šafin, together with the ambassadors of the Visegrad Group visited the cities of Severodonetsk and Lysychansk. A visit to the Luhansk Regional Cardiology Center and the Regional Children's Clinic in Lysychansk was part of the program. On this occasion, the Slovak Ambassador gave the Director of the Children's Clinic, S. Ošeko, humanitarian aid from the International Visegrad Fund, consisting of 7,200 RT-qPCR tests from the Slovak company MultiplexDX, which will be used for early diagnosis of COVID-19.

A gift of 10,000 COVID-19 diagnostic kits produced by Slovak company MultiplexDX was presented to the Pope during the audience of the Slovak President, Zuzana Čaputova, on December 14th.

Source: Office of the President of the Slovak Republic


Pope Francis’ decision to receive refugees on Vatican soil, as well as his help for the homeless and asylum seekers, is the embodiment of the values ​​of humanity and solidarity. We can imagine how difficult it is to provide help to people in pandemic conditions and to ensure their safety. That is why MultiplexDX decided to support Pope Francis’ efforts by donating 10,000 PCR tests from Slovakia, which were developed and manufactured by our scientists.

Our gift to Vatican facilities that provide shelter and care for people in need was handed over personally by Slovak President Zuzana Čaputová and CEO of MultiplexDX Dr. Pavol Čekan, who was also part of the delegation.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News